Skip to main content

EDITORIAL article

Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1476475
This article is part of the Research Topic Immune-checkpoint Inhibitors in Anti-cancer Armamentarium: a Double-edged Sword in Risk of Developing Autoimmunity and Immune-related Adverse Effects View all 10 articles

Editorial: "Immune-checkpoint Inhibitors in Anti-cancer Armamentarium: A Double-edged Sword in Risk of Developing Autoimmunity and Immune-related Adverse Effects."

Provisionally accepted
  • 1 School of Infection and Immunity, University of Glasgow, Glasgow, Scotland, United Kingdom
  • 2 Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Italy., Perugia, Italy
  • 3 Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France
  • 4 Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus

The final, formatted version of the article will be published soon.

    Keywords: cancer immuno therapy, immune-checkpoint inhibitors (ICIs), Immune-related adverse events, Autoimmunity, Anti-CTLA 4, Anti-PD 1/L1

    Received: 05 Aug 2024; Accepted: 12 Aug 2024.

    Copyright: © 2024 Tulunay Virlan, Cafaro, Sunzini, Degboé and Christodoulou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Maria-Ioanna (Marianna) Christodoulou, School of Infection and Immunity, University of Glasgow, Glasgow, G12 8TA, Scotland, United Kingdom

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.